Dan Janiak

BlackThorn Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted medicines for the treatment of central nervous system (CNS) disorders. With pathfinder™, our computational psychiatry platform, our approach is based on generating a quantitative, brain-based understanding of neurobehavioral disorders. These data-driven insights are applied to create treatments targeted to biologically-based subtypes of patients to increase the precision of therapeutic intervention. Our clinical pipeline is designed to restore balance to dysregulated brain circuits and empower individuals with CNS disorders to live better lives. BlackThorn is headquartered in San Francisco, California. For more information, please visit blackthornrx.com.

Confluence Discovery Technologies (CDT) is a full-service pharmaceutical contract research organization that focuses on early-stage drug discovery and development pursuits. We believe that our individually tailored research solutions paired with our extensive experience in the pharmaceutical discovery and development process help us deliver unmatched partnerships to accelerate each of our client’s unique project goals. From a conceptual new drug idea to the filing of an Investigational New Drug Application, we can support each step of the drug discovery pipeline with services targeting: • Biochemistry and Mechanistic Enzymology • Cell and Molecular Biology • Custom Assay Development and Validation • Biomarkers and Translational Biology • Immunology and Immuno-oncology • In Vivo Pharmacology • Medicinal, Computational and Bioanalytical Chemistry • Project Management • R&D Consultation CDT’s highly trained scientists operate in a state-of-the-art laboratory in Saint Louis, Missouri, to provide superior quality, yet affordable research solutions in the heart of the United States. We prioritize in-depth data analysis, consultation and industry expertise in each collaboration and value our experience on challenging drug targets and complex biological systems. To learn more about our fully integrated drug discovery research strategies, please visit our website (confluencediscovery.com) or complete our Contact Us form to inquire about specific solutions to expedite your research needs.

Working to solve chronic sinusitis

DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The company’s lead product candidate is DNX-2401, which is expected to enter into a global pivotal Phase 3 clinical study for patients with recurrent glioblastoma. DNX-2401 is also being evaluated in a Phase 1 study for diffuse intrinsic pontine glioma, for which it has received FDA Fast Track and Rare Pediatric Disease designations. A second product candidate, DNX-2440, is entering a Phase 1 clinical study in patients with colorectal and other cancers with liver metastasis. The company’s investors include Morningside Ventures and Mercury Fund.

Confluence Life Sciences, Inc. is a research company based out of 4320 FOREST PARK AVE, Saint Louis, Missouri, United States.

BlackThorn Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted medicines for the treatment of central nervous system (CNS) disorders. With pathfinder™, our computational psychiatry platform, our approach is based on generating a quantitative, brain-based understanding of neurobehavioral disorders. These data-driven insights are applied to create treatments targeted to biologically-based subtypes of patients to increase the precision of therapeutic intervention. Our clinical pipeline is designed to restore balance to dysregulated brain circuits and empower individuals with CNS disorders to live better lives. BlackThorn is headquartered in San Francisco, California. For more information, please visit blackthornrx.com.

Mercury is an early-stage venture capital firm partnering with entrepreneurs to drive innovation across Middle America. Mercury’s investment themes target B2B SaaS and B2B2C marketplace platforms enabling the digital transformation of markets, industries, and customer relationships. With $750M under management, Mercury has created over $9 billion of value with an operationally focused investment strategy helping startups achieve rapid, sustainable growth. Mercury is headquartered in Houston with offices in Austin, Texas and Ann Arbor, Michigan. To learn more visit mercuryfund.com.

Confluence Discovery Technologies (CDT) is a full-service pharmaceutical contract research organization that focuses on early-stage drug discovery and development pursuits. We believe that our individually tailored research solutions paired with our extensive experience in the pharmaceutical discovery and development process help us deliver unmatched partnerships to accelerate each of our client’s unique project goals. From a conceptual new drug idea to the filing of an Investigational New Drug Application, we can support each step of the drug discovery pipeline with services targeting: • Biochemistry and Mechanistic Enzymology • Cell and Molecular Biology • Custom Assay Development and Validation • Biomarkers and Translational Biology • Immunology and Immuno-oncology • In Vivo Pharmacology • Medicinal, Computational and Bioanalytical Chemistry • Project Management • R&D Consultation CDT’s highly trained scientists operate in a state-of-the-art laboratory in Saint Louis, Missouri, to provide superior quality, yet affordable research solutions in the heart of the United States. We prioritize in-depth data analysis, consultation and industry expertise in each collaboration and value our experience on challenging drug targets and complex biological systems. To learn more about our fully integrated drug discovery research strategies, please visit our website (confluencediscovery.com) or complete our Contact Us form to inquire about specific solutions to expedite your research needs.

Working to solve chronic sinusitis